Treatment and Evaluation Advances in Leprosy Neuropathy View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-11-19

AUTHORS

Gigi J. Ebenezer, David M. Scollard

ABSTRACT

Neuropathy and related disabilities are the major medical consequences of leprosy, which remains a global medical concern. Despite major advances in understanding the mechanisms of M. leprae entry into peripheral nerves, most aspects of the pathogenesis of leprosy neuropathy remain poorly understood. Sensory loss is characteristic of leprosy, but neuropathic pain is sometimes observed. Effective anti-microbial therapy is available, but neuropathy remains a problem especially if diagnosis and treatment are delayed. Currently there is intense interest in post-exposure prophylaxis with single-dose rifampin in endemic areas, as well as with enhanced prophylactic regimens in some situations. Some degree of nerve involvement is seen in all cases and neuritis may occur in the absence of leprosy reactions, but acute neuritis commonly accompanies both Type 1 and Type 2 leprosy reactions and may be difficult to manage. A variety of established as well as new methods for the early diagnosis and assessment of leprosy neuropathy are reviewed. Corticosteroids offer the primary treatment for neuritis and for subclinical neuropathy in leprosy, but success is limited if nerve function impairment is present at the time of diagnosis. A candidate vaccine has shown apparent benefit in preventing nerve injury in the armadillo model. The development of new therapeutics for leprosy neuropathy is greatly needed. More... »

PAGES

1-14

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13311-021-01153-z

DOI

http://dx.doi.org/10.1007/s13311-021-01153-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1142705388

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34799845


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Neurology/Cutaneous Nerve Laboratory, Johns Hopkins University, The John G Rangos Bldg, room: 440, 855 North Wolfe Street, Baltimore, MD 21205 USA", 
          "id": "http://www.grid.ac/institutes/grid.21107.35", 
          "name": [
            "Neurology/Cutaneous Nerve Laboratory, Johns Hopkins University, The John G Rangos Bldg, room: 440, 855 North Wolfe Street, Baltimore, MD 21205 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ebenezer", 
        "givenName": "Gigi J.", 
        "id": "sg:person.013146403627.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013146403627.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Hansen\u2019s Disease Programs, Baton Rouge, LA 70816 USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "National Hansen\u2019s Disease Programs, Baton Rouge, LA 70816 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scollard", 
        "givenName": "David M.", 
        "id": "sg:person.01126146616.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126146616.98"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41541-018-0050-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101598143", 
          "https://doi.org/10.1038/s41541-018-0050-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep19570", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035652678", 
          "https://doi.org/10.1038/srep19570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2377-12-159", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006200216", 
          "https://doi.org/10.1186/1471-2377-12-159"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12879-018-3402-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107433396", 
          "https://doi.org/10.1186/s12879-018-3402-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41541-018-0055-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103975524", 
          "https://doi.org/10.1038/s41541-018-0055-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12879-019-4665-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1124199673", 
          "https://doi.org/10.1186/s12879-019-4665-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncprheum0898", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024441109", 
          "https://doi.org/10.1038/ncprheum0898"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002560050584", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038862059", 
          "https://doi.org/10.1007/s002560050584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar419", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012915794", 
          "https://doi.org/10.1186/ar419"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-11-19", 
    "datePublishedReg": "2021-11-19", 
    "description": "Neuropathy and related disabilities are the major medical consequences of leprosy, which remains a global medical concern. Despite major advances in understanding the mechanisms of M. leprae entry into peripheral nerves, most aspects of the pathogenesis of leprosy neuropathy remain poorly understood. Sensory loss is characteristic of leprosy, but neuropathic pain is sometimes observed. Effective anti-microbial therapy is available, but neuropathy remains a problem especially if diagnosis and treatment are delayed. Currently there is intense interest in post-exposure prophylaxis with single-dose rifampin in endemic areas, as well as with enhanced prophylactic regimens in some situations. Some degree of nerve involvement is seen in all cases and neuritis may occur in the absence of leprosy reactions, but acute neuritis commonly accompanies both Type 1 and Type 2 leprosy reactions and may be difficult to manage. A variety of established as well as new methods for the early diagnosis and assessment of leprosy neuropathy are reviewed. Corticosteroids offer the primary treatment for neuritis and for subclinical neuropathy in leprosy, but success is limited if nerve function impairment is present at the time of diagnosis. A candidate vaccine has shown apparent benefit in preventing nerve injury in the armadillo model. The development of new therapeutics for leprosy neuropathy is greatly needed.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13311-021-01153-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1294839", 
        "issn": [
          "1933-7213", 
          "1878-7479"
        ], 
        "name": "Neurotherapeutics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }
    ], 
    "keywords": [
      "leprosy neuropathy", 
      "leprosy reactions", 
      "type 2 leprosy reactions", 
      "single-dose rifampin", 
      "nerve function impairment", 
      "post-exposure prophylaxis", 
      "time of diagnosis", 
      "anti-microbial therapy", 
      "acute neuritis", 
      "nerve involvement", 
      "subclinical neuropathy", 
      "neuropathic pain", 
      "prophylactic regimens", 
      "nerve injury", 
      "sensory loss", 
      "function impairment", 
      "candidate vaccines", 
      "peripheral nerves", 
      "primary treatment", 
      "early diagnosis", 
      "related disability", 
      "neuropathy", 
      "endemic areas", 
      "medical consequences", 
      "neuritis", 
      "type 1", 
      "new therapeutics", 
      "medical concerns", 
      "leprosy", 
      "diagnosis", 
      "apparent benefit", 
      "treatment", 
      "armadillo model", 
      "global medical concern", 
      "major advances", 
      "prophylaxis", 
      "corticosteroids", 
      "pain", 
      "regimens", 
      "nerve", 
      "pathogenesis", 
      "therapy", 
      "vaccine", 
      "injury", 
      "rifampin", 
      "impairment", 
      "disability", 
      "most aspects", 
      "therapeutics", 
      "involvement", 
      "intense interest", 
      "advances", 
      "assessment", 
      "absence", 
      "cases", 
      "benefits", 
      "entry", 
      "loss", 
      "mechanism", 
      "concern", 
      "reaction", 
      "development", 
      "consequences", 
      "success", 
      "time", 
      "degree", 
      "area", 
      "variety", 
      "aspects", 
      "method", 
      "situation", 
      "interest", 
      "model", 
      "new method", 
      "problem", 
      "major medical consequences", 
      "leprae entry", 
      "Effective anti-microbial therapy", 
      "Evaluation Advances"
    ], 
    "name": "Treatment and Evaluation Advances in Leprosy Neuropathy", 
    "pagination": "1-14", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1142705388"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13311-021-01153-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34799845"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13311-021-01153-z", 
      "https://app.dimensions.ai/details/publication/pub.1142705388"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T19:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_878.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13311-021-01153-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01153-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01153-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01153-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13311-021-01153-z'


 

This table displays all metadata directly associated to this object as RDF triples.

181 TRIPLES      22 PREDICATES      112 URIs      95 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13311-021-01153-z schema:about anzsrc-for:11
2 anzsrc-for:1109
3 schema:author Na2a7e98eabb24a8e831223517ed156bf
4 schema:citation sg:pub.10.1007/s002560050584
5 sg:pub.10.1038/ncprheum0898
6 sg:pub.10.1038/s41541-018-0050-z
7 sg:pub.10.1038/s41541-018-0055-7
8 sg:pub.10.1038/srep19570
9 sg:pub.10.1186/1471-2377-12-159
10 sg:pub.10.1186/ar419
11 sg:pub.10.1186/s12879-018-3402-4
12 sg:pub.10.1186/s12879-019-4665-0
13 schema:datePublished 2021-11-19
14 schema:datePublishedReg 2021-11-19
15 schema:description Neuropathy and related disabilities are the major medical consequences of leprosy, which remains a global medical concern. Despite major advances in understanding the mechanisms of M. leprae entry into peripheral nerves, most aspects of the pathogenesis of leprosy neuropathy remain poorly understood. Sensory loss is characteristic of leprosy, but neuropathic pain is sometimes observed. Effective anti-microbial therapy is available, but neuropathy remains a problem especially if diagnosis and treatment are delayed. Currently there is intense interest in post-exposure prophylaxis with single-dose rifampin in endemic areas, as well as with enhanced prophylactic regimens in some situations. Some degree of nerve involvement is seen in all cases and neuritis may occur in the absence of leprosy reactions, but acute neuritis commonly accompanies both Type 1 and Type 2 leprosy reactions and may be difficult to manage. A variety of established as well as new methods for the early diagnosis and assessment of leprosy neuropathy are reviewed. Corticosteroids offer the primary treatment for neuritis and for subclinical neuropathy in leprosy, but success is limited if nerve function impairment is present at the time of diagnosis. A candidate vaccine has shown apparent benefit in preventing nerve injury in the armadillo model. The development of new therapeutics for leprosy neuropathy is greatly needed.
16 schema:genre article
17 schema:inLanguage en
18 schema:isAccessibleForFree true
19 schema:isPartOf sg:journal.1294839
20 schema:keywords Effective anti-microbial therapy
21 Evaluation Advances
22 absence
23 acute neuritis
24 advances
25 anti-microbial therapy
26 apparent benefit
27 area
28 armadillo model
29 aspects
30 assessment
31 benefits
32 candidate vaccines
33 cases
34 concern
35 consequences
36 corticosteroids
37 degree
38 development
39 diagnosis
40 disability
41 early diagnosis
42 endemic areas
43 entry
44 function impairment
45 global medical concern
46 impairment
47 injury
48 intense interest
49 interest
50 involvement
51 leprae entry
52 leprosy
53 leprosy neuropathy
54 leprosy reactions
55 loss
56 major advances
57 major medical consequences
58 mechanism
59 medical concerns
60 medical consequences
61 method
62 model
63 most aspects
64 nerve
65 nerve function impairment
66 nerve injury
67 nerve involvement
68 neuritis
69 neuropathic pain
70 neuropathy
71 new method
72 new therapeutics
73 pain
74 pathogenesis
75 peripheral nerves
76 post-exposure prophylaxis
77 primary treatment
78 problem
79 prophylactic regimens
80 prophylaxis
81 reaction
82 regimens
83 related disability
84 rifampin
85 sensory loss
86 single-dose rifampin
87 situation
88 subclinical neuropathy
89 success
90 therapeutics
91 therapy
92 time
93 time of diagnosis
94 treatment
95 type 1
96 type 2 leprosy reactions
97 vaccine
98 variety
99 schema:name Treatment and Evaluation Advances in Leprosy Neuropathy
100 schema:pagination 1-14
101 schema:productId N6db907abe4c44029b9c58f49d726133c
102 N8c54e99c7ede4f4fbe4e84244dec2983
103 Ndc139de8c1f04a5e9925f4181e7346d5
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142705388
105 https://doi.org/10.1007/s13311-021-01153-z
106 schema:sdDatePublished 2022-01-01T19:01
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher Nd81fc6bff7c3485cabffd12ea764e521
109 schema:url https://doi.org/10.1007/s13311-021-01153-z
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N3bd64672551e42f08af217f17c6caf70 rdf:first sg:person.01126146616.98
114 rdf:rest rdf:nil
115 N6db907abe4c44029b9c58f49d726133c schema:name dimensions_id
116 schema:value pub.1142705388
117 rdf:type schema:PropertyValue
118 N8c54e99c7ede4f4fbe4e84244dec2983 schema:name doi
119 schema:value 10.1007/s13311-021-01153-z
120 rdf:type schema:PropertyValue
121 Na2a7e98eabb24a8e831223517ed156bf rdf:first sg:person.013146403627.23
122 rdf:rest N3bd64672551e42f08af217f17c6caf70
123 Nd81fc6bff7c3485cabffd12ea764e521 schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 Ndc139de8c1f04a5e9925f4181e7346d5 schema:name pubmed_id
126 schema:value 34799845
127 rdf:type schema:PropertyValue
128 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
129 schema:name Medical and Health Sciences
130 rdf:type schema:DefinedTerm
131 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
132 schema:name Neurosciences
133 rdf:type schema:DefinedTerm
134 sg:journal.1294839 schema:issn 1878-7479
135 1933-7213
136 schema:name Neurotherapeutics
137 schema:publisher Springer Nature
138 rdf:type schema:Periodical
139 sg:person.01126146616.98 schema:affiliation grid-institutes:None
140 schema:familyName Scollard
141 schema:givenName David M.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126146616.98
143 rdf:type schema:Person
144 sg:person.013146403627.23 schema:affiliation grid-institutes:grid.21107.35
145 schema:familyName Ebenezer
146 schema:givenName Gigi J.
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013146403627.23
148 rdf:type schema:Person
149 sg:pub.10.1007/s002560050584 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038862059
150 https://doi.org/10.1007/s002560050584
151 rdf:type schema:CreativeWork
152 sg:pub.10.1038/ncprheum0898 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024441109
153 https://doi.org/10.1038/ncprheum0898
154 rdf:type schema:CreativeWork
155 sg:pub.10.1038/s41541-018-0050-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1101598143
156 https://doi.org/10.1038/s41541-018-0050-z
157 rdf:type schema:CreativeWork
158 sg:pub.10.1038/s41541-018-0055-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103975524
159 https://doi.org/10.1038/s41541-018-0055-7
160 rdf:type schema:CreativeWork
161 sg:pub.10.1038/srep19570 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035652678
162 https://doi.org/10.1038/srep19570
163 rdf:type schema:CreativeWork
164 sg:pub.10.1186/1471-2377-12-159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006200216
165 https://doi.org/10.1186/1471-2377-12-159
166 rdf:type schema:CreativeWork
167 sg:pub.10.1186/ar419 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012915794
168 https://doi.org/10.1186/ar419
169 rdf:type schema:CreativeWork
170 sg:pub.10.1186/s12879-018-3402-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107433396
171 https://doi.org/10.1186/s12879-018-3402-4
172 rdf:type schema:CreativeWork
173 sg:pub.10.1186/s12879-019-4665-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124199673
174 https://doi.org/10.1186/s12879-019-4665-0
175 rdf:type schema:CreativeWork
176 grid-institutes:None schema:alternateName National Hansen’s Disease Programs, Baton Rouge, LA 70816 USA
177 schema:name National Hansen’s Disease Programs, Baton Rouge, LA 70816 USA
178 rdf:type schema:Organization
179 grid-institutes:grid.21107.35 schema:alternateName Neurology/Cutaneous Nerve Laboratory, Johns Hopkins University, The John G Rangos Bldg, room: 440, 855 North Wolfe Street, Baltimore, MD 21205 USA
180 schema:name Neurology/Cutaneous Nerve Laboratory, Johns Hopkins University, The John G Rangos Bldg, room: 440, 855 North Wolfe Street, Baltimore, MD 21205 USA
181 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...